8-30-0



ractitioner's Docket No MPI2000-368P1R(M)

PATENT

Preliminary Classification:

THE REPORT OF THE PROPERTY OF THE PARTY OF T

Proposed Class:

Subclass:

NOTE: "All applicants are requested to include a preliminary classification on newly filed patent applications. The preliminary classification, preferably class and subclass designations, should be identified in the upper right-hand corner of the letter of transmittal accompanying the application papers, for example 'Proposed Class 2, subclass 129." M.P.E.P. Section 601, 7th ed.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Box Patent Application Assistant Commissioner for Patents Washington, D.C. 20231



NEW APPLICATION TRANSMITTAL

Transmitted herewith for f	filing is the	patent application o	f
----------------------------	---------------	----------------------	---

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) AND 1.10*

(When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

[X] deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. Section 1.8(a)

37 C.F.R. Section 1.10*

[] with sufficient postage as first class mail. [X] as "Express Mail Post Office to Address" Mailing Label No. EL 791760317 US (mandatory)

TRANSMISSION

[]	transmitted	by facsimile	to the Patent	and Trademark	Office	(703)

Date: August 29, 2001

(type or print name of person certifying)

*WARNING:

Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. Section 1.10(b).

"Since the filing of correspondence under [Section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(New Application Transmittal--page 1 of7)

Inventor(s):GLUCKSMANN, Maria Alexandra; GIMENO, Ruth; and WHITE, David

WARNING:

THE REPORT OF THE PROPERTY OF

37 C.F.R. Section 1.41(a)(1) points out:

"(a) A patent is applied for in the name or names of the actual inventor or inventors.

(1) The inventorship of a nonprovisional application is that inventorship set forth in the oath or declaration as prescribed by Section 1.63, except as provided for in Section 1.53(d)(4) and Section 1.63(d). If an oath or declaration as prescribed by Section 1.63 is not filed during the pendency of a nonprovisional application, the inventorship is that inventorship set forth in the application papers filed pursuant to Section 1.53(b), unless a petition under this paragraph accompanied by the fee set forth in Section 1.17(i) is filed supplying or changing the name or names of the inventor or inventors."

For (title): 57242, A Novel Human G Protein-Coupled Receptor Family Member and Uses Therefor

1. Type of Application

This new application is for a(n)

(check one applicable item below)

[X]	Original (nonprovisional)
[]	Design
[]	Plant

NOTE: If one of the following 3 items apply, then complete and attach ADDED PAGES FOR NEW APPLICATION
TRANSMITTAL WHERE BENEFIT OF A PRIOR U.S. APPLICATION CLAIMED and a NOTIFICATION IN PARENT
APPLICATION OF THE FILING OF THIS CONTINUATION APPLICATION.

[]	Divisional.
[]	Continuation.
[]	Continuation-in-part (C-I-P)

2. Benefit of Prior U.S. Application(s) (35 U.S.C. Sections 119(e), 120, or 121)

[X] The new application being transmitted claims the benefit of prior U.S. Provisional Application No. 60/228409 filed 29-Aug-2000 under 35 U.S.C. Sections 119(e).

3. Papers Enclosed

A. Required for Filing Date under 37 C.F.R. Section 1.53(b) (Regular) or 37 C.F.R. Section 1.153 (Design) Application

97 Pages of Specification12 Pages of Claims0 Sheets of Drawing

(New Application Transmittal--page 2 of 7)

	В.	Other Papers Enclosed 4 Pages of declaration and power of attorney 1 Pages of Abstract Other
4.	Additi	onal Papers Enclosed
	[]	Amendment to claims
		[] Cancel in this applications claims before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
		[] Add the claims shown on the attached amendment. (Claims added have been numbered consecutively following the highest numbered original claims.)
	[]	Preliminary Amendment Information Disclosure Statement (37 C.F.R. Section 1.98) Form PTO-1449 (PTO/SB/08A and 08B) Citations Deplement of Riclosical Deposit
	[] [X]	Declaration of Biological Deposit Submission of Sequence Listing: Transmittal Letter for Diskette Containing Sequence Listing, paper copy (4 pages) of Sequence Listing; and computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or
	[] [] []	amino acid sequence. Authorization of Attorney(s) to Accept and Follow Instructions from Representative Special Comments Other
5.	Declar	ration or Oath (including power of attorney)
	[X]	Enclosed (Unexecuted)
		 [] inventor(s). [] legal representative of inventor(s). 37 C.F.R. Section 1.42 or 1.43. [] joint inventor or person showing a proprietary interest on behalf of inventor who refused to sign or cannot be reached. [] This is the petition required by 37 C.F.R. Section 1.47 and the statement required by 37 C.F.R. Section 1.47 is also attached. See item 13 below
	[]	for fee. Not Enclosed.
vorr		
NOTE:		he filing is a completion in the U.S. of an International Application, or where the completion of the U.S. ion contains subject matter in addition to the International Application, the application may be treated as a

continuation or continuation-in-part, as the case may be, utilizing ADDED PAGE FOR NEW APPLICATION

TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION CLAIMED.

(New Application Transmittal--page 3 of 7)

1.16(d)

Multiple Dependent Claim(s), if any (37 C.F.R. Section

\$270.00

		[]		ntion is made by a ve named invento		uthorized	under 37 C.F.I	R. 1.41 or	behalf of all
	(The d	eclaratio	on or oath	n, along with the s can be fil	_	_	by 37 C.F.R. S	Section 1.	16(e),
			[]	Showing that the (not required unit				R. Section	1.41(d))
6.	Assign	ment							
	[X]	An ass	signment	of the invention to	o <u> </u>	<u> Iillennium</u>	Pharmaceutic	als, Inc.	
		[]	MENT)	ned. A separate [ACCOMPANY] 95 is also attache	NG NEV				
		[X]	will fol		a.				
WARN	ING:			STATEMENT UNDE filed by an assignee. I					ntinuation-in-
7.	Fee Ca	alculatio		F.R. Section 1.16 application)				
				CLAIN	AS AS F	LED			
Claim	S	Num	ber Filed	Basic Fee Allowance	Numl	ber Extra	Rate		
Total (37 C. Section 1.16(c.	n	20		- 20 =	0	x	\$18.00	\$	
	endent C F.R. Sec		3	- 3 =	0	X	\$80.00	\$	\$80.00

(New Application Transmittal--page 4 of 7)

|--|

A party
1920
more in
÷
-
2;
IJ
Ļ
and The
Ž.

NOTE:	expirati		ra claims are not paid on filing they must be paid or the claims car ime period set for response by the Patent and Trademark Office in an	
			Filing Fee Calculation	\$
	В.	[] (\$320	Design application 1.0037 C.F.R. Section 1.16(f)) Filing Fee Calculation	\$
	C.	[] (\$490	Plant application 9.0037 C.F.R. Section 1.16(g)) Filing Fee Calculation	\$
		Filing	Fee Calculation (50% of A , B or C above) \$	
8.	Fee Pa	ayment l	Being Made at This Time	
	[X]	Not E	inclosed	
		[X]	No filing fee is to be paid at this time. (This and the surcharge required by 37 C.F.R. S subsequently.)	ection 1.16(e) can be po
	[]	Enclo	sed	
		[]	Filing fee	\$
		[]	Recording assignment (\$40.00; 37 C.F.R. Section 1.21(h)) (See attached "COVER SHEET FOR ASSIGNMENT ACCOMPANYING NEW APPLICATION.")	\$
		[]	Petition fee for filing by other than all the inventors or person on behalf of the inventor where inventor refused to sign or cannot be reached (\$130.00; 37 C.F.R. Sections 1.47 and 1.17(i))\$	
		[]	For processing an application with a specification in a non-English language (\$130.00; 37 C.F.R. Sections 1.52(d) and 1.17(k))\$	
		[]	Processing and retention fee	

(New Application Transmittal--page 5 of 7)

			(\$130.00; 37 C.F.R. Sections 1.53(d) and	1.21(1))\$
		[]	Fee for international-type search report (\$40.00; 37 C.F.R. Section 1.21(e))	\$
NOTE:	complete and 1.78(the applic a)(1), indi	1.21(1) establishes a fee for processing and retaining attion pursuant to 37 C.F.R. Section 1.53(f) and this, icate that in order to obtain the benefit of a prior U.S. and retention fee of Section 1.21(1) must be paid, within	as well as the changes to 37 C.F.R. Section 1.53 application, either the basic filing fee must be paid,
			Total Fees Enclosed	\$
9.	Method	l of Pay	ment of Fees	
	[]	Check	in the amount of \$	
	[]		e Account No. 501668 in the amount of \$	·
NOTE:	Fees show	ıld be iten	nized in such a manner that it is clear for which purpos	te the fees are paid. 37 C.F.R. Section 1.22(b).
10.	Author	ization	to Charge Additional Fees	
WARNI	NG:	If no fee	s are to be paid on filing, the following items should \underline{n}	ot be completed.
WARNI	NG:		ely count claims, especially multiple dependent claim: are authorized.	s, to avoid unexpected high charges, if extra claim
	[]		commissioner is hereby authorized to charge and during the entire pendency of this application.	
		[]	37 C.F.R. Section 1.16(a), (f) or (g) (filing	g fees)
		[]	37 C.F.R. Section 1.16(b), (c) and (d) (pre	sentation of extra claims)
NOTE:	or these o	claims can ficiency (3	fees for excess or multiple dependent claims not paid acelled by amendment prior to the expiration of the tin 37 C.F.R. Section 1.16(d)), it might be best not to a en dealing with amendments after final action.	ne period set for response by the PTO in any notice
		[]	37 C.F.R. Section 1.16(e) (surcharge declaration on a date later than the filing of	
		[]	37 C.F.R. Section 1.17(a)(1)-(5) (extension	on fees pursuant to Section 1.136(a).
		[]	37 C.F.R. Section 1.17 (application proces	ssing fees)
NOTE:	requiring	a petition	may be submitted in an application that is an auth n for an extension of time under this paragraph for its or the appropriate length of time. An authorization to c	s timely submission, as incorporating a petition for

all required extension of time fees will be treated as a constructive petition for an extension of time in any concurrent or

(New Application Transmittal--page 6 of 13)

future reply requiring a petition for an extension of time under this paragraph for its timely submission. Submission of the fee set forth in Section 1.17(a) will also be treated as a constructive petition for an extension of time in any concurrent reply requiring a petition for an extension of time under this paragraph for its timely submission." 37 C.F.R. Section 1.136(a)(3).

[] 37 C.F.R. Section 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. Section 1.311(b))

NOTE: Where an authorization to charge the issue fee to a deposit account has been filed before the mailing of a Notice of Allowance, the issue fee will be automatically charged to the deposit account at the time of mailing the notice of allowance.

37 C.F.R. Section 1.311(b)).

NOTE: 37 C.F.R. Section 1.28(b) requires "Notification of any change in status resulting in loss of entitlement to small entity status must be filed in the application . . . prior to paying, or at the time of paying, . . issue fee." From the wording of 37 C.F.R. Section 1.28(b), (a) notification of change of status must be made even if the fee is paid as "other than a small entity" and (b) no notification is required if the change is to another small entity.

11. Instructions as to Overpayment

NOTE: "... Amounts of twenty-five dollars or less will not be returned unless specifically requested within a reasonable time, nor will the payer be notified of such amounts; amounts over twenty-five dollars may be returned by check or, if requested, by credit to a deposit account." 37 C.F.R. Section 1.26(a).

[X]	Credit Account No	501668	
[]	Refund		

Date: August 29, 2001

THE RESERVE OF THE PERSON OF T

SIGNATURE OF PRACTITIONER

Reg. No. . 47,066

Kerri Pollard Schray
(type or print name of practitioner)

Tel. No.: (617) 551-3676

Millennium Pharmaceuticals 75 Sidney Street

73 Siuney Sueet

Cambridge, MA 02139

P.O. Address

Customer No.:

[X] Statement Where No Further Pages Added

(if no further pages form a part of this Transmittal, then end this Transmittal with this page and check the following item)

[X] This transmittal ends with this page.

(New Application Transmittal--page 7 of 7)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Glucksmann, et al.

Serial No.: To Be Assigned

Filed: Herewith

For: 57242, A Novel Human G-Protein-Coupled Receptor Family Member and Uses Therefor

Attorney Docket No.: MPI2000-368P1R(M)

Assistant Commissioner for Patents Box Sequence Washington, D.C. 20231

TRANSMITTAL LETTER FOR DISKETTE CONTAINING SEQUENCE LISTING

Dear Sir:

Enclosed is a diskette which contains a computer readable form of the Sequence Listing for the patent application filed herewith. The Sequence Listing complies with the requirements of 37 C.F.R. § 1.821. The material on this diskette is identical in substance to the Sequence Listing which is submitted herewith, as required by 37 C.F.R. § 1.821(f). The computer readable form of the sequence listing contained on the enclosed diskette is understood to comply with the requirements of § 1.824(d).

Express Mail" mailing label number EL 791760317 US
Date of Deposit August 29, 2001
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box Sequence Washington D.C. 20231 Signature
Please Print Name of Person Signing · ANDREW BOYD

MILLENNIUM PHARMACEUTICALS, INC.

Kerri Pollard Schray, Ph.D.
Registration No.: 47,066

Attorney for Applicant

Millennium Pharmaceuticals, Inc.

75 Sidney Street

Cambridge, MA 02139 Telephone: 617-551-3676 Facsimile: 617-551-8820